drugset
drugset / Trial / NCT07054346

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

NCT07054346 ↗

Phase 1 Recruiting 45 enrolled Thomas Hope Novartis · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.

Timeline

Start
2025-07-08
Primary completion
2027-04-30
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-PSMA-617 Other / unclassified — Intravenous
Subject AAA817 Other / unclassified — Intravenous

Indications

prostate carcinoma